Tratamiento antiangiogénico en fondo de distrofia de Sorsby sin mutación en gen de TIMP-3

The known mutations in TIMP-3 may not be extended to all patients with SFD. The use of intravitreal ranibizumab may be considered as a therapeutic option in CNV secondary to SFD.